Key Points
- Blake Borgeson sold 220,000 shares of Recursion on Jan. 6 at an average price of $4.36 for about $959,200, trimming his stake by 3.2% to 6,649,863 shares.
- Recursion reported a $0.36 loss per share and revenue of $5.18 million for the quarter, a decline of 80.1% year‑over‑year and well below the $19.36 million analysts expected.
- The stock is trading near recent lows (opened at $4.70; 12‑month low $3.79) with mixed analyst coverage and a consensus “Hold” rating and average target of $9.40.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 220,000 shares of the business's stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $4.36, for a total value of $959,200.00. Following the completion of the sale, the director owned 6,649,863 shares of the company's stock, valued at $28,993,402.68. The trade was a 3.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, December 2nd, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.37, for a total value of $961,400.00.
Recursion Pharmaceuticals Trading Down 3.3%
Shares of NASDAQ RXRX opened at $4.70 on Friday. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The firm has a market cap of $2.44 billion, a PE ratio of -2.61 and a beta of 0.95. The business has a fifty day simple moving average of $4.48 and a two-hundred day simple moving average of $5.06. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The firm had revenue of $5.18 million for the quarter, compared to analyst estimates of $19.36 million. During the same quarter last year, the firm posted ($0.34) earnings per share. The business's revenue for the quarter was down 80.1% on a year-over-year basis. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have weighed in on RXRX shares. Needham & Company LLC restated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. UBS Group set a $11.00 price target on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Morgan Stanley set a $11.00 price objective on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $10.00 to $11.00 in a research note on Wednesday, December 17th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $9.40.
Read Our Latest Research Report on RXRX
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Breakwater Capital Group acquired a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $81,000. 180 Wealth Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 65.7% during the fourth quarter. 180 Wealth Advisors LLC now owns 93,201 shares of the company's stock valued at $381,000 after acquiring an additional 36,971 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Recursion Pharmaceuticals by 5.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 419,618 shares of the company's stock valued at $2,048,000 after purchasing an additional 20,115 shares during the last quarter. Hudson Bay Capital Management LP boosted its stake in Recursion Pharmaceuticals by 50.0% in the 3rd quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company's stock worth $1,098,000 after purchasing an additional 75,000 shares in the last quarter. Finally, Allworth Financial LP grew its position in Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company's stock worth $47,000 after purchasing an additional 4,403 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
